News Detail
BOSTON, 3 JAN 2025: Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane condu......
View Details
Source : Vertex Pharmaceuticals
triple-combination CFTR modulator therapy
vanzacaftor
tezacaftor
deutivacaftor
U.S. Food and Drug Administration (FDA)
Vertex Pharmaceuticals
Alyftrek
Related News
- Complaints filed with FDA and CMO against Solapur Ayush manufacturer; owner refutes allegations (05-01-2025)
- MP FDA forms joint team with Centre to ensure revised Schedule M compliance in pharma cos (05-01-2025)
- Draft notification for extension of Schedule M published for comments (04-01-2025)
- Illegal medical shop busted in Hyderabad (04-01-2025)
- Rajasthan: Registration of psychiatric hospitals, doctors will be mandatory (04-01-2025)
- TSMC serves notice to Rushcare Hospitals for its alleged association with quacks (04-01-2025)
- Pharma teachers faking profiles at multiple institutions, face being blacklisted (04-01-2025)
- DCA officials seize falsely manufactured Calcium tablets worth Rs 1.5 lakh (04-01-2025)
- Cancer drugs present strongest innovation pipeline in next 5 years: Report (04-01-2025)
- US FDA Releases Draft Guidance on Sampling and Testing of In-Process Materials and Drug Products (04-01-2025)